FDA Inspection
White House Pharmacy Inc. dba San Jose Compounding PharmacyWhite House Pharmacy Inc. dba San Jose Compounding Pharmacy – FDA Inspection, Sep 14, 2018
Record Details
This FDA Inspection record concerns White House Pharmacy Inc. dba San Jose Compounding Pharmacy, with an inspection on September 14, 2018, issued by the San Francisco District Office, covering human drugs.
- Inspection Date
- September 14, 2018
- Product Type
- Human Drugs
View Company Profile
ID · 191108b6-3740-417a-956d-fd96ca492f69
Inspection Facts
- Inspection number
- 1065880
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
4- FDCA 501(a)(2)(A)Beta-lactam drugs, inadequate sanitation
- FDCA 501(a)(2)(A)Hazardous drugs, prevention of cross-contamination
- FDCA 501(a)(2)(A)Highly potent drugs, prevention of cross-contamination
- FDCA 501(a)(2)(A)Use of non-pharmaceutical grade components
Full citation text and observation details available on the Dashboard.
Other FDA inspections of White House Pharmacy Inc. dba San Jose Compounding Pharmacy
1| Date | Classification | Office | Project area |
|---|---|---|---|
| June 15, 2021 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for White House Pharmacy Inc. dba San Jose Compounding Pharmacy
- FDA Inspection 1146258 - 2021-06-15
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.